MarketMoodz
TEM — Tempus AI, Inc.
Is TEM overbought or oversold? Here is the current MarketMoodz read.
Tempus AI, Inc. (TEM) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $49.36. The rating moved from Overbought to Neutral on August 14, 2026.
- Public ratingNeutral (as of August 19, 2026)
- Last close$49.36
- Last changeMoved from Overbought to Neutral on August 14, 2026
- SectorHealthcare
- IndustryHealth Information Services
AI analysis
Tempus AI, Inc. (TEM) benefits from a deep clinical-genomic data asset and an AI-driven analytics platform positioned at the intersection of oncology diagnostics, drug development and clinical decision support. Recent market rotation into AI growth names and positive readthroughs in diagnostics provide near-term momentum, while commercial partnerships and recurring analytics revenue offer a path to scale. Key challenges include execution risk converting models into dependable revenue, regulatory/privacy scrutiny of health data practices, and potential cash-burn or dilution if growth requires external funding. Near-term scenarios range from accelerated commercialization and meaningful topline growth to slower adoption and margin pressure if reimbursement, competition, or regulatory issues intensify.
Key factors
- Large, proprietary clinical-genomic dataset and analytics platform that supports precision oncology and AI model development
- Favorable AI and diagnostics thematic tailwind (market rotation into AI growth names and increasing demand for AI-enabled diagnostic tools)
- Readthroughs from recent oncology/biologics data and device clearances that expand addressable markets for diagnostic and AI-enabled products
- Partnership and commercial opportunity with biopharma, CROs and healthcare systems for data-driven drug development and clinical decision support
- Potential for revenue acceleration from product commercialization and recurring analytics/subscription services if adoption climbs
- Market sentiment: constructive social-media chatter around AI earnings and reduced hedging, supporting near-term upside momentum
Risks
- Execution and commercialization risk: converting data and models into consistent, scalable revenue streams is not guaranteed
- Regulatory and privacy risk (FTC attention to digital-health data practices and potential enforcement or litigation)
- Funding/cash-burn risk: if organic cash flow is insufficient, equity dilution or costly financings could pressure the stock
- Reimbursement and payer pressure: insurers and PBMs tightening coverage or pricing could limit adoption
- Intense competition from established diagnostics firms and large tech companies entering healthcare AI
- Sensitivity to macro/geopolitical headlines and short-term sentiment swings that can amplify volatility
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TEM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.